J. Meltzer

发表

T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G

U. Dirksen, E. Wardelmann, M. Fluegge, 2017, Oncotarget.

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

M. Fluegge, H. Wiendl, A. Jacobs, 2017, Oncoimmunology.

Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency

C. Rossig, K. Grobe, B. Altvater, 2021, Cancer reports.

Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.

U. Dirksen, J. Hardes, C. Rossig, 2014, Oncology reports.

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo

N. Sebire, M. Hotfilder, C. Rossig, 2010, Leukemia.

HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells

W. Hartmann, D. Görlich, C. Rossig, 2021, Cancers.

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

M. Fluegge, W. Hartmann, K. Kerl, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting

U. Dirksen, J. Hardes, G. Gosheger, 2012, British Journal of Cancer.

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

M. Fluegge, H. Wiendl, A. Jacobs, 2017, Oncoimmunology.

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process

A. Schambach, W. Berdel, W. Hartmann, 2023, Cancer Gene Therapy.